Frontier Biotechnologies Inc. Class ASSE: 688221

"Frontier Biotechnologies Inc."Voluntary Disclosure Announcement on Obtaining Drug Registration Certificate for FB3002 Loxoprofen Sodium Patches

Aug 21, 2026 · Issued by Frontier Biotechnologies Inc. Class A via Shanghai Stock Exchange

Voluntary Disclosure Announcement on Obtaining Drug Registration Certificate for FB3002 Loxoprofen Sodium Patches

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Frontier Biotechnologies Inc. Class A

"Frontier Biotechnologies Inc."Indicative Announcement on Change in Equity of Shareholders Holding More Than 5% of the Shares Reaching 1% and 5% ThresholdAug 13
"Frontier Biotechnologies Inc."Announcement on Returning Idle Raised Funds Used to Temporarily Supplement Current CapitalJul 11
"Frontier Biotechnologies Inc."Announcement on Abnormal Fluctuations in Stock TradingJul 3
Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Annual ReportJun 13

All Frontier Biotechnologies Inc. Class A news releases